The ability to block pro-inflammatory cytokines, such as TNF-α and IL-17, would elevate the efficacy of new treatment agents evaluated in RA animal experiments and clinical trials [26, 27]. The gene discussed is IL17A; the disease is rheumatoid arthritis.